Skip to content

Fascial Abdominal Closure Evaluation

A Randomized Trial of Duramesh Versus PDS Loop Suture for Midline Incision Fascial Abdominal Closure Evaluation in Patients With Gynecological Malignancies

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07683546
Acronym
FACE
Enrollment
300
Registered
2026-07-06
Start date
2026-09-01
Completion date
2029-03-31
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duramesh, Hernia Incisional, Suture Materials

Brief summary

FACE (Fascial Abdominal Closure Evaluation) Trial is a prospective, single center, open-label, randomized trial of Duramesh versus PDS loop suture for midline incision fascial abdominal closure evaluation in patients with gynecological malignancies

Detailed description

Incisional hernias after midline incisions are estimated are estimated around 10-20%, which many times results in further surgical procedures. Many techniques with different sutures have been proposed of the years for fascial closure. PDS suture offers longer dissolution time, lower short-term tensile strength and lower knot security, however the highest quality data available for gynecological malignancies are from 30 years ago. On the other hand, the use of mesh suture (Duramesh) has been proposed as an alternative, in order to reduce postoperative hernias and abdominal wall complication rates. A recent systematic review on Duramesh shows promising results with a median incisional hernia occurrence of 3.4%, but the authors highlight the need for high-quality randomized controlled trials with long-term follow-up to evaluate the clinical benefits of Duramesh.

Interventions

DEVICEDURAMESH

Duramesh is a non-absorbable polypropylene "mesh suture": a suture that is built like a tiny mesh tube so it behaves both as a suture and as a small piece of mesh to strengthen tissue closure

DEVICE(Ethicon) PDS II 1-0 double loop

(Ethicon) PDS II 1-0 double loop suture with a 48 mm needle is a slowly absorbable, synthetic monofilament polydioxanone suture designed to provide prolonged tensile support for fascial and other soft-tissue closure where extended wound support is desired

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

* ARM A: Control Arm: Continuous technique fascial closure with small bite widths of 0,5cm and inter suture spacing of 0,5cm with the use of (Ethicon) PDS II 1-0 double loop suture material with a 48mm needle. If the incision's length is over 20cm, 2 sutures will be used (starting from top and bottom, respectively). * ARM B: Intervention Arm: Continuous technique fascial closure with small bite widths of 0,5cm and inter suture spacing of 0,5cm with the use of Duramesh\* with a 48mm needle. If the incision's length is over 20cm, 2 sutures will be used (starting from top and bottom, respectively).

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Midline laparotomies for gynecological malignancies * Age 18 - 85 years old * ECOG Performance status: 0 - 2

Exclusion criteria

* Pregnancy * Albumin \< 3.5 g/dL * Previous history of any type of hernia * Previous midline incision (via laparotomy)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of incisional herniaUp to 12 months after randomizationClinical or radiological detected

Secondary

MeasureTime frameDescription
Incidence of wound dehiscenceUp to 1 month after randomization
Incidence of wound infectionUp to 1 months after randomization
Visual Analogue Scale (VAS) for wound painFifth postoperative day after randomizationWound pain will be assessed with the Visual Analogue Scale (VAS). The minimum value is 0 (no pain) and the maximum value is 10 (Pain as bad as it could possibly be). The VAS line is 10cm long. Higher scores mean a worse outcome.

Contacts

CONTACTDimitrios Zouzoulas, MD, MSc, PhD
dzouzoulas@hotmail.gr+306946536065
PRINCIPAL_INVESTIGATORDimitrios Tsolakidis, Dr. Prof.

Aristotle University Of Thessaloniki

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026